|Bid||53.26 x 46200|
|Ask||53.99 x 2000|
|Day's Range||123.10 - 126.90|
|52 Week Range||90.20 - 129.85|
|PE Ratio (TTM)||38.69|
|Forward Dividend & Yield||0.85 (0.69%)|
|1y Target Est||N/A|
Ipsen SA.’s (ENXTPA:IPN) released its most recent earnings update in December 2017, which revealed that the company gained from a strong tailwind, leading to a double-digit earnings growth of 19.57%.Read More...
French pharma company Ipsen (IPN.PA) expects to bring more drugs to combat cancer, rare diseases and mobility impairment into its pipeline this year and has around one billion euros (888.29 million pounds) for asset purchases, its chief executive said. Ipsen's shares were up 10.03 percent at 1205 GMT, among top performers on the STOXX 600 (.STOXX) index. Ipsen Chief Executive David Meek told Reuters the company would continue to buy in new drugs which it could then take through its research and development channels and to the market.
IPSEN (IPSEY) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
Commercial Vehicle Group, MTS Systems, Ipsen, AXA and Arkema highlighted as Zacks Bull and Bear of the Day
The CAC 40 index achieved its highest close since Aug 2015 as investors welcomed the prospect of Macron becoming France's next president.